Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection

dc.contributor.authorArtman, Chaden
dc.contributor.authorIdegwu, Nnebuefeen
dc.contributor.authorBrumfield, Kyle D.en
dc.contributor.authorLai, Kenen
dc.contributor.authorHauta, Shirleyen
dc.contributor.authorFalzarano, Darrylen
dc.contributor.authorParreño, Vivianaen
dc.contributor.authorYuan, Lijuanen
dc.contributor.authorGeyer, James D.en
dc.contributor.authorGoepp, Julius G.en
dc.date.accessioned2022-11-10T18:24:24Zen
dc.date.available2022-11-10T18:24:24Zen
dc.date.issued2022-10-27en
dc.date.updated2022-11-10T14:27:14Zen
dc.description.abstractBackground: Human norovirus (HuNoV) is the leading viral cause of diarrhea, with GII.4 as the predominant genotype of HuNoV outbreaks globally. However, new genogroup variants emerge periodically, complicating the development of anti-HuNoV vaccines; other prophylactic or therapeutic medications specifically for HuNoV disease are lacking. Passive immunization using oral anti-HuNoV antibodies may be a rational alternative. Here, we explore the feasibility of using avian immunoglobulins (IgY) for preventing HuNoV infection in vitro in a human intestinal enteroid (HIE) model. Methods: Hens were immunized with virus-like particles (VLP) of a GII.4 HuNoV strain (GII.4/CHDC2094/1974/US) by intramuscular injection. The resulting IgY was evaluated for inhibition of binding to histo-blood group antigens (HBGA) and viral neutralization against representative GII.4 and GII.6 clinical isolates, using an HIE model. Results: IgY titers were detected by three weeks following initial immunization, persisting at levels of 1:2<sup>21</sup> (1:2,097,152) from 9 weeks to 23 weeks. Anti-HuNoV IgY significantly (<i>p</i> &lt; 0.05) blocked VLP adhesion to HBGA up to 1:12,048 dilution (0.005 mg/mL), and significantly (<i>p</i> &lt; 0.05) inhibited replication of HuNoV GII.4[P16] Sydney 2012 in HIEs up to 1:128 dilution (0.08 mg/mL). Neutralization was not detected against genotype GII.6. Conclusions: We demonstrate the feasibility of IgY for preventing infection of HIE by HuNoV GII.4. Clinical preparations should cover multiple circulating HuNoV genotypes for comprehensive effects. Plans for animal studies are underway.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationArtman, C.; Idegwu, N.; Brumfield, K.D.; Lai, K.; Hauta, S.; Falzarano, D.; Parreño, V.; Yuan, L.; Geyer, J.D.; Goepp, J.G. Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection. Viruses 2022, 14, 2371.en
dc.identifier.doihttps://doi.org/10.3390/v14112371en
dc.identifier.urihttp://hdl.handle.net/10919/112557en
dc.language.isoenen
dc.publisherMDPIen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleFeasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infectionen
dc.title.serialVirusesen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
viruses-14-02371.pdf
Size:
998.63 KB
Format:
Adobe Portable Document Format
Description:
Published version
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description: